SureTrader SPDR Advertisement SPDR Advertisement
Home > Boards > US OTC > Biotechs >

PharmaCyte Biotech Inc. (PMCB)

PMCB RSS Feed
Add PMCB Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator mick, bulldurham, TraderpennyX, Peacefulwendy, TheBestInvest, $Pistol Pete$
Search This Board:
Last Post: 7/30/2015 11:46:45 PM - Followers: 544 - Board type: Free - Posts Today: 0

Welcome to PharmaCyte BioTech
 

$PMCB Enjoy Corporate Video

 


 

$PMCB Enjoy Discovery Channel Video

 



 

$PMCB Enjoy Another Great Video YouTube TGen Leads the Way in Early Detection of Cancer. Dr. Von Hoff will lead $PMCB into FDA Fast Track Approval

 

 
 

 


FDA Grants Orphan Drug Designation to Nuvilex for Pancreatic Cancer Treatment

http://www.nuvilex.com/latest-news/149-fda-grants-orphan-drug-designation-to-nuvilex-for-pancreatic-cancer-treatment








Encapsulated Cells Expressing a Chemotherapeutic Activating Enzyme Allow the Targeting of Subtoxic Chemotherapy and Are Safe and Efficacious:
Data from Two Clinical Trials in Pancreatic Cancer

http://www.mdpi.com/1999-4923/6/3/447




















ThaiTECT ???????? 14 - Drug Development Part I : International Experiences

http://www.youtube.com/watch?v=nL_LznwTdKk


Nuvilex/Austrianova declared the winner of the 2014 Best Innovation Award
 
http://client.irwebkit.com/Nuvilex/news/2433458






Encapsulation of Insulin Producing Cells for Diabetes Treatment Using 
Alginate and Cellulose Sulphate as Bioencapsulation Polymers


http://austrianova.com/wp-content/uploads/2014/09/DRTOA-1-102-final.compressed.pdf


NUVILEX (NVLX)- The Next Great Biotech Story (VIDEO)

                                            

PharmaCyte Company Address
   PharmaCyte BioTech, Inc.
   Meadows Corporate Park I
   12510 Prosperity Dr., Suite #310
   Silver Spring, MD 20904-1643
   Phone:  (877) 958-7616 , (917) 595-2850
   Fax: (917) 595-2851
   email:
 info@pharmacytebiotech.com


Market Value:
$76,201,902 a/o Mar 11, 2015

Shares Outstanding:
699,292.029 a/o Dec 15, 2014

Authorized Shares:
1,490,000,000 a/o Aug 26, 2014

Float:
529,206,849 a/o Aug 26, 2014


Short Selling Data

Short Interest: 363,107 (1.685) a/o Feb 13, 2015

For more updated information please visit: 


http://www.otcmarkets.com/stock/PMCB/profile


Transfer Agent:
Signature  Stock Transfer Inc. Plano TX  Ph # 972-612-4120

Investor Relations


Jamien Jones 
Blueprint Life Science Group 
Telephone: 415.375.3340 Ext. 103 
jjones@bplifescience.com 

http://bplifescience.com/clients.html 

                                               

All News Releases: 
http://www.nuvilex.com/latest-news

All Information about Nuvilex:
http://www.stockmarketmediagroup.com/features/nvlx/

What is Cell-in-a-Box®?

The Cell-in-a-Box® technology, developed by Austrianova, is a means to protect, isolate, storeand transport living cells. The proprietary technology can be used for a variety of purposes.
In healthcare, it facilitates the safe implantation of cells, holding them isolated from the immune system and allowing long term production of therapeutic molecules in patients. 
In biotechnology, the Cell-in-a-Box® technology protects cells in bioreactors and fermenters, while at the same time simplifying purification of bioproducts produced from the cells and reducing production cost. 
The technology can also be applied to probiotics, cosmetics and agriculture, environmental protection and monitoring, as well as forming the basis of a powerful research tool. 
The company’s proprietary cell packaging material, Gel8, used for the Cell-in-a-Box® technology, is derived from a naturally occurring material and is thus harmless to the environment, biologically inert and has been shown to be safe in humans.


http://austrianova.com/products/ 



PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. PharmaCyte Biotech's treatment for pancreatic cancer involves low doses of the well-known anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or "cancer-killing" form. These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This "targeted chemotherapy" has proven remarkably effective in past clinical trials. In addition, PharmaCyte Biotech is working towards improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors.



">

Austria Nova Demonstration Video

 
 

SMMG Radio Interview with COO Dr. Crabtree ~ 2013





Shareholder Update with CEO & COO via SMMG Interview ~ July 2014






The proprietary technology can be used for a variety of purposes.

In healthcare, it facilitates the safe implantation of cells, holding them isolated from the immune system and allowing long term production of therapeutic molecules in patients.

In biotechnology, the Cell-in-a-Box™ technology protects cells in bioreactors and fermenters, while at the same time simplifying purification of bioproducts produced from the cells and reducing production cost.

The technology can also be applied to probiotics, cosmetics and agriculture, environmental protection and monitoring, as well as forming the basis of a powerful research tool


Management Team:

 

Kenneth L. Waggoner, Chief Executive Officer and President:


Further highlights of Mr. Waggoner’s career include leadership and legal positions with several start-up companies during the last several years as well as working with Fortune 500 companies most of his professional career.  During his tenure with Chevron, Mr. Waggoner served as the Vice President and General Counsel of its Global Downstream operations where he was responsible for the overall management of legal services to the North American, Latin American, Europe and Asian Products Companies.  At Chevron he led a successful restructuring of the company’s international Legal Department following Chevron’s acquisition of Texaco.Kenneth L. Waggoner has almost four decades of experience in management, business, operations and law.  Mr. Waggoner started his career as an attorney in private practice. Notably he was a senior partner with Brobeck, Phleger and Harrison, named one of the top two law firms worldwide that provide services to biotechnology clients including Chiron, Amgen, Biogen Idec, Sangamo, Ligand, DepoTech and many others.  He was the Managing Partner of Brobeck’s Los Angeles office.  Mr. Waggoner was also a member of the Executive Committee for almost ten years and on the Policy Committee for numerous years managing Brobeck’s worldwide operations with annual revenues in excess of $750,000,000.  While at Brobeck, Mr. Waggoner was the Co-Chairman of Brobeck’s world-wide Environmental Law Group.

Mr. Waggoner received his Juris Doctorate. with honors in 1973 from Loyola University School of Law in Los Angeles.

 

Gerald W. Crabtree, Ph.D. – Chief Operating Officer and Director:



Dr. Crabtree is the Company’s Chief Operating Officer.  Since 1985, Dr. Crabtree has been involved with various biopharmaceutical companies where he has alternatively supervised and coordinated the development of multiple drug candidates, prepared clinical protocols, investigator brochures, monographs, research and review articles and served as project manager for development of major oncologic agents.  He is a Member of the American Society of Clinical Oncology and also is a past member of research grant review committees for the National Institute of Health and the American Cancer Society.  Dr. Crabtree established and directed, from inception, a department that monitored and coordinated the development of oncologic and immunologic drugs from initial discovery through regulatory approval in a major pharmaceutical company and served as project manager for the development of the anticancer agent, Taxol®.

Dr. Crabtree received his Ph.D. in Biochemistry from the University of Alberta, Edmonton, Alberta, Canada and has published over 80 articles in peer-reviewed journals.  He is a National Cancer Institute of Canada Research Fellow.  In addition, he served as Department Head of Molecular Pharmacology for the Nucleic Acid Research Institute, and prior to that as Associate Professor of Medicine with the Roger Williams Cancer Center at Brown University.  Dr. Crabtree has also served as Director of Project Planning and Management (Oncology/Immunology) at Bristol-Myers Squibb and as Vice-President of Research and Development at ETEX Corporation.  Most recently, Dr. Crabtree served as Interim CEO of PhytoCeutica, Inc., where he assisted in preparation and review of FDA documents, clinical study protocols, investment acquisitions and contracts and business plans.

Walter H. Gunzburg – Chief Scientific Officer:



Prof. Walter H. Gunzburg is the co-founder, Chairman of the Board and Chief Technical Officer of Austrianova. As well as being a full Professor of Virology at the University of Vienna since 1996, he has had many years of experience in the biotech industry. He was a scientific advisor to the international vaccine company, Bavarian Nordic, from 1994-2001 and was involved in their IPO. He has also been an scientific advisor to the German biotech companies, Paktis and Liponova, as well as the U.S. biotech company, Tocagen Inc., all of which developed/are developing advanced medicinal treatments for cancer. He was also the Director of the Christian Doppler Laboratory for Gene Therapeutic Vector Development from 2003-2011. Currently, he is a board member of ViruSure, a virus and prion testing company located in Vienna that he cofounded.

Prof. Gunzburg has been actively involved in European ethics and regulatory affairs in the fields of cell and gene therapy as well as xenotransplantation for many years. He was a member of the German Medical Association's Central Commission for Somatic Gene Therapy. He has also interacted with a number of regulatory agencies including the US FDA, EMA, TGA, HSA and Thai-FDA and was on the review panel for the Paul Ehrlich Institute, Langen, Germany. Prof. Gunzburg continues to be an active researcher and has published more than 130 peer-reviewed publications in international scientific and medical journals such as NatureThe Lancet,Proceedings of the National Academy of Sciences USA and Cancer Research as well as co-authoring the first German language textbook on gene therapy. He is also a member of the editorial board of a number of international cell and gene therapy journals including Trends in Molecular Medicine, and continues to be an active reviewer for many top tier journals as well as grant funding agencies.


Dr. Matthias Lohr as Chairman of Scientific Advisory Board:



Matthias Löhr was appointed professor of gastroenterology & hepatology at Karolinska Institutet in 2007, incoming from the Univ. Heidelberg/dkfz. From the times of his MD thesis through PhD and lateron, he concentrated on several aspects of the pancreas, both in clinical medicine, translational and basic sciences. He is heading the Pancreas Research Team at Gastrocentrum and leading the KICancer Diagnose-related network for HPB tumors. For hte European Gastroenterologists (UEG), he is sitting in several committees at the EU in Brussels. He is also leading the Pancreas 2000 program, an educational program for future pancreatologists in Europe.

Thomas Liquard - Chairman of the Audit Committe


Mr. Liquard is a seasoned pharmaceutical industry executive whose past experiences include serving as Chief Executive of Alchemia Limited and as Senior Director, Portfolio Development Leader, Emerging Markets for the Established Products portfolio for Pfizer in New York.

 

Dr. Eva Maria (Lilli) Brandtner – Director of Diabetes Program Development




 

Following receipt of her Doctorate in Natural Sciences in the areas of Biochemical Microbiology and Molecular Genetics in 2001, Dr. Brandtner served as a Postdoctoral Scientist and Senior Postdoctoral Fellow at Austrianova Biomanufacturing AG in Austria where she was involved in the development of retroviral vectors for gene therapy.  In 2007, Dr. Brandtner moved to Singapore and became Project Manager for work on the cell-based therapy of liver cancer at the same company.  Shortly thereafter, Dr. Brandtner was promoted to Senior Scientist at Austrianova Pte Ltd (Austrianova) where she oversaw the development of numerous projects concerned with live cell Bioencapsulation.  This was followed in 2010 by her promotion to Chief Scientist at Austrianova, responsible for all encapsulation projects in medicine and biology.  Most importantly, while at Austrianova, Dr. Brandtner was intimately involved in all of the preclinical work done there that included the use of live cell encapsulation in developing a treatment for insulin-dependent diabetes.  Due to family commitments, in 2012 Dr. Brandtner left Singapore to return to Austria where she is currently employed as Head of the Bioencapsulation Unit at the Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT).

Dr. Brandtner is co-inventor on two granted patents and is named on several additional patents that are in preparation.  She has co-authored numerous research reports that have been published in reputable scientific journals and has presented research results at national and international scientific conferences and meetings.  Dr. Brandtner is a member of the European Association for the Study of Diabetes (EASD), the Austrian Diabetes Association (ÖDG) and the European Society for Gene and Cell Therapy (ESGCT).

Dr. Manuel Hidalgo, Scientific Advisory Board:



Manual Hidalgo is the Vice Director of Translational Research, Clinical Research Program Director and Head of Gastrointestinal Cancer Clinical Research Unit at the Spanish National Cancer Research Centre (CNIO) and Director at the Centro Integral Oncologico Clara Campal (CIOCC). In addition he is a professor of Oncology at the University CEU San Pablo. Dr. Hidalgo was born in Antequera, Malaga, in 1968. He received his MD from the Universidad de Navarra, Pamplona, in 1992 and his PhD from the Universidad Autonoma de Madrid in 1997. Manuel specialized in Medical Oncology at the Hospital Universitario 12 de Octubre, Madrid, obtaining his license in 1996. He completed his training in drug development at the University of Texas Health Science Center, San Antonio (USA), where he briefly joined as Faculty. He then moved to Johns Hopkins University in 2001 as Co-Director of the Drug Development and GI Programs. He joined the CNIO in 2009 to lead the GI Cancer Clinical Research Unit. Manuel is a founding member of the Pancreatic Cancer Research Team (PCRT) - a clinical trials group focusing on novel therapeutics for pancreatic cancer. He has participated in the clinical development of more than 30 novel anticancer agents and led the early clinical trials with erlotinib and temsirolimus - two recently approved drugs. Manuel´s work has contributed to the incorporation of molecular endpoints in early clinical trials. His group pioneered the utilization of personalized xenograft models for drug screening, biomarker development and personalized cancer treatment. He has published more than 180 papers in peer-reviewed journals and his work has been funded by the NCI, AACR, and ASCO. Manuel received an AACR Clinical Research Fellowship and an ASCO Career Development Award for his work on the development of EGFR inhibitors. His most recent efforts focus on novel therapeutics for pancreatic cancer. - See more at: http://www.imagingendpoints.com/about/meet-our-team/scientific-advisory-board#sthash.o9zIWGIR.dpuf



 

 






Stock Chart http://www.otcmarkets.com/stock/NVLX/chart
Company Info http://www.otcmarkets.com/stock/NVLX/company-info
Recent News http://www.otcmarkets.com/stock/NVLX/news
Financials http://www.otcmarkets.com/stock/NVLX/financials
Filings and Disclosure http://www.otcmarkets.com/stock/NVLX/filings
Short Sales http://www.otcmarkets.com/stock/NVLX/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/NVLX/insider-transactions
Research Reports http://www.otcmarkets.com/stock/NVLX/research
Summary http://finance.yahoo.com/q?s=NVLX
Historical Prices http://finance.yahoo.com/q/hp?s=NVLX+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=NVLX
Basic Chart http://finance.yahoo.com/q/bc?s=NVLX+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=NVLX+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=NVLX+Headlines
Press Releases http://finance.yahoo.com/q/p?s=NVLX+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=NVLX+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=NVLX+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=NVLX+Industry
Major Holders http://finance.yahoo.com/q/mh?s=NVLX+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=NVLX+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=NVLX+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=NVLX
Balance Sheet http://finance.yahoo.com/q/bs?s=NVLX
Cash Flow http://finance.yahoo.com/q/cf?s=NVLX+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/NVLX
Market Watch http://www.marketwatch.com/investing/stock/NVLX
Bloomberg http://www.bloomberg.com/quote/NVLX:US
Morningstar http://quotes.morningstar.com/stock/s?t=NVLX
Bussinessweek http://investing.businessweek.com/research/st...icker=NVLX
Barchart http://www.barchart.com/quotes/stocks/NVLX
OTC Short Report http://otcshortreport.com/index.php?index=NVLX
Investopedia http://www.investopedia.com/markets/stocks/NVLX/?wa=0

Features http://www.stockmarketmediagroup.com/features/nvlx/

 

                                  

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PMCB
Current Price
Volume:
Bid Ask Day's Range
Wiki
PMCB News: Annual Report (10-k) 07/29/2015 04:05:04 PM
PMCB News: PharmaCyte Biotech Begins Second Follow-Up Study on Ascites 07/23/2015 09:20:00 AM
PMCB News: PharmaCyte Biotech Appoints Renowned Oncologist Dr. Manuel Hidalgo to Scientific Advisory Board 07/16/2015 09:10:00 AM
PMCB News: Notification That Annual Report Will Be Submitted Late (nt 10-k) 07/14/2015 04:16:53 PM
PMCB News: PharmaCyte Biotech Drug Delivery Platform Limited only by Imagination 07/09/2015 10:00:00 AM
PostSubject
#38732  Sticky Note $PMCB ~ PharmaCyte Biotech, Inc. due dilig $Pistol Pete$ 07/21/15 12:14:58 AM
#38724  Sticky Note Ken Waggoner, our CEO.... Peacefulwendy 07/20/15 05:26:36 PM
#37735  Sticky Note WOW... All that in under 4 minutes on Discovery Channel... bulldurham 06/30/15 09:10:50 AM
#37576  Sticky Note $PMCB Breaking News PharmaCyte Biotech’s Cancer a $Pistol Pete$ 06/29/15 09:08:57 AM
#36793  Sticky Note $PMCB Treatment Being Studied Involves a Combo of $Pistol Pete$ 06/17/15 03:58:32 PM
#31423  Sticky Note PharmaCyte Biotech Initiates First Preclinical Study of Its TheBestInvest 02/04/15 11:38:18 AM
#18112  Sticky Note EVERYONE please keep your posts on-topic. The topic IH Geek [Dave] 03/14/14 12:28:20 PM
#39088   $PMCB Daily Chart For Review $Pistol Pete$ 07/30/15 11:46:45 PM
#39087   Great post, thanks. Peacefulwendy 07/30/15 09:24:28 PM
#39086   $PMCB This Biotech Company Could Redefine the Meaning $Pistol Pete$ 07/30/15 07:05:54 PM
#39085   Not everyone it hasn't been two years since spiritthing 07/30/15 07:05:00 PM
#39084   What are you talking about? The $1.220M that Going Coastal 07/30/15 04:39:10 PM
#39083   I doubt that is the answer. avobill 07/30/15 03:33:48 PM
#39082   NOT MUCH OF A DISCOVERY - PMBC put BioNewton 07/30/15 03:20:47 PM
#39081   Would like to know how pmcb expects to frosr6 07/30/15 01:17:16 PM
#39079   Dilution is the way things are paid for BioNewton 07/30/15 11:33:55 AM
#39078   But the gains the company has made have JDT188 07/30/15 11:30:39 AM
#39077   Dilution. Shares outstanding as of 7/30/13: 509.9mm Shares A_realist 07/30/15 11:19:03 AM
#39076   After reading the 10k and understanding that PMCB BioNewton 07/30/15 11:04:11 AM
#39075   PMCB 64 days left in the quarter and thenewmixer 07/30/15 10:22:24 AM
#39074   Another reason to hold off on PMCB. Dilution. A_realist 07/30/15 09:51:14 AM
#39073   Another reason the technology is better today. BioNewton 07/30/15 09:26:57 AM
#39072   PharmaCyte Biotech's Improved Technology Attracting World Class Oncologists BioNewton 07/30/15 09:23:08 AM
#39071   For those that wonder why CiaB is better BioNewton 07/30/15 09:20:42 AM
#39070   We have seen this. BioNewton 07/30/15 07:19:48 AM
#39069   Page 7 pancreatic cancer. http://www.ema.europa.eu/docs/en_GB/document_library/ frosr6 07/30/15 06:44:02 AM
#39068   Looking like its getting ready to go Pete The Promised Land 07/30/15 03:15:55 AM
#39067   $PMCB Daily Chart $Pistol Pete$ 07/30/15 03:12:17 AM
#39066   Congrats ;-) Go $PMCB $Pistol Pete$ 07/29/15 09:40:42 PM
#39065   '$Pistol Pete$', I added another 1,000 shares today pennyvestor 07/29/15 09:20:21 PM
#39063   $PMCB Reversal of diabetes following trans $Pistol Pete$ 07/29/15 07:27:56 PM
#39062  Restored No, they did not report it and it Peacefulwendy 07/29/15 07:09:02 PM
#39060   LMAO, PharmaCyte isn't going to pr a bad frosr6 07/29/15 06:55:47 PM
#39059   Looks to me like we are going full Peacefulwendy 07/29/15 06:17:44 PM
#39058   can you show me a link where PMCB thenewmixer 07/29/15 05:40:16 PM
#39057   I was just trying to give you an Peacefulwendy 07/29/15 05:37:46 PM
#39056   Well, Cell in a Box(R) technology has only Peacefulwendy 07/29/15 05:28:13 PM
#39055   Fros, the good news is that this is Peacefulwendy 07/29/15 05:22:00 PM
#39054   NOTE 17 – SUBSEQUENT EVENTS From May 1, frosr6 07/29/15 05:19:48 PM
#39053   The FDA will still need to approve but Peacefulwendy 07/29/15 05:11:49 PM
#39051   We are made aware of that each year BioNewton 07/29/15 04:49:40 PM
#39050   Guess what like I said they're selling shares frosr6 07/29/15 04:45:02 PM
#39049   Well we know the application was withdrawn. Peacefulwendy 07/29/15 04:42:49 PM
#39048   I think if a person needs everything to Peacefulwendy 07/29/15 04:37:57 PM
#39047   Then KW should not have made a false thenewmixer 07/29/15 04:29:29 PM
#39046   Since this initial study for ascites, there have Peacefulwendy 07/29/15 04:27:32 PM
#39044   do your DD as you said you have...its thenewmixer 07/29/15 04:21:20 PM
#39043   Guess what is out! 10k BioNewton 07/29/15 04:17:00 PM
#39042   I was able to dispute everything that was BioNewton 07/29/15 04:15:41 PM
#39041   Mixer, can you provide the link for that Peacefulwendy 07/29/15 04:13:23 PM
#39040   I proved PMCBs dog and pony show.....all delays thenewmixer 07/29/15 04:08:59 PM
#39039   What does that mean? Please explain what BioNewton 07/29/15 04:02:32 PM
#39038   The 10k is actually not late. They BioNewton 07/29/15 04:00:04 PM
#39036   Oh I'm sorry. Do you have PMCB's latest frosr6 07/29/15 03:16:29 PM
#39035   current market cap divided by shares outstanding A_realist 07/29/15 03:10:45 PM
#39034   here some old stuff about PMCB thenewmixer 07/29/15 03:10:18 PM
#39033   Are you figuring in the (set whatever price frosr6 07/29/15 03:05:15 PM
PostSubject